News Sentiment

FBRX sentiment intelligence

Forte Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 61 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 43.92 Week of 10 Jul 2026
Weighted tone 61/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

+109.9% over one week, +150.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Forte Biosciences stock hits 52-week high at $45.39

Market Reaction

Price moving ahead of tone

72/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 109.9% Price confirming higher
Trend fit Trend inactive 150.1% over four weeks
Fair value 168.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 31
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
Market source 7
TradingView 6
Seeking Alpha 5
Investing.com 4
marketscreener.com 3
TradingKey 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 20
Deals and strategy 1
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
TradingView Direct company coverage

Price to book forward of Forte Biosciences, Inc. – NASDAQ:FBRX

The article focuses on the "Price to book forward" financial metric for Forte Biosciences, Inc. (NASDAQ: FBRX). It is presented as part of TradingView's financial data offerings for the biotechnology company. The content appears to be a stub or a section within a larger financial

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:13
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Forte Biosciences Inc. – FWB:37T

This article provides the enterprise value to revenue forward for Forte Biosciences Inc., traded on the Frankfurt Stock Exchange under the symbol FWB:37T. It highlights the financial data available for the company, indicating the market is currently closed with no trades. The con

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 10:10
Source
TradingView
StocksToTrade Direct company coverage

FBRX Stock Soars As FB102 Vitiligo Data Ignite Biotech Momentum

Forte Biosciences Inc. (FBRX) stock surged by 13.65% after announcing positive Phase 1b clinical trial data for its FB102 vitiligo treatment, showing significant facial vitiligo improvements, durable off-drug benefits, and a clean safety profile. This strong data has increased in

Tone
Positive 70/100
Event
Market update
Published
10 Jul 2026 16:20
Source
StocksToTrade
Kavout | AI Direct company coverage

Forte Biosciences' Vitiligo Triumph: A High-Stakes Bet on Broad Autoimmune Potential

Forte Biosciences' stock surged after positive Phase 1b clinical trial results for its drug candidate, FB102, in vitiligo patients. The study showed statistically significant improvements in vitiligo symptoms with a favorable safety profile and sustained efficacy post-treatment.

Tone
Positive 85/100
Event
Earnings
Published
10 Jul 2026 16:09
Source
Kavout | AI
TradingView Direct company coverage

FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data

Forte Biosciences (FBRX) shares surged 78.3% following positive top-line results from a phase Ib study of FB102 for vitiligo. The study showed statistically significant improvements in facial depigmentation and a favorable safety profile for FB102, boosting investor confidence. T

Tone
Positive 86/100
Event
Earnings
Published
10 Jul 2026 15:39
Source
TradingView
Sahm Direct company coverage

Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study

Forte Biosciences' FB102 drug showed significant efficacy and a favorable safety profile in an early-stage study for vitiligo, a skin pigmentation disorder. The Phase 1b trial demonstrated statistically significant improvements in facial repigmentation, with benefits continuing e

Tone
Positive 82/100
Event
Market update
Published
10 Jul 2026 15:09
Source
Sahm
Market source Direct company coverage

Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement

Forte Biosciences announced that its drug FB102 met its primary endpoint in a small, placebo-controlled vitiligo study, demonstrating a statistically significant and durable improvement in facial Vitiligo Area Scoring Index. The study showed continued improvement in patients even

Tone
Positive 73/100
Event
Market update
Published
10 Jul 2026 14:09
Source
Market source
Seeking Alpha Direct company coverage

Forte Bio surges on early-stage trial data for vitiligo therapy

Forte Biosciences' stock surged after the company released early-stage trial data for its lead asset, FB102, a vitiligo therapy. The results showed a statistically significant improvement in vitiligo symptoms as early as nine weeks, leading to a positive market reaction for FBRX.

Tone
Positive 93/100
Event
Earnings
Published
10 Jul 2026 03:11
Source
Seeking Alpha
TipRanks Direct company coverage

Forte Biosciences Reports Positive Phase 1b Vitiligo Results

Forte Biosciences reported positive results from its Phase 1b trial of FB102 for vitiligo, showing a significant mean improvement in facial vitiligo and a favorable safety profile. These findings support the potential of FB102 and the company's broader autoimmune pipeline, includ

Tone
Positive 95/100
Event
Earnings
Published
09 Jul 2026 14:41
Source
TipRanks
Market source Direct company coverage

Forte Biosciences Shares Climb After Positive Phase 1b Vitiligo Trial Results (FBRX)

Forte Biosciences (NASDAQ:FBRX) shares rose 12% following positive results from its Phase 1b trial of FB102 for vitiligo. The study demonstrated statistically significant improvements in facial repigmentation, particularly in patients with more extensive disease, and showcased a

Tone
Positive 93/100
Event
Earnings
Published
09 Jul 2026 14:09
Source
Market source
Investing.com Direct company coverage

Forte Biosciences stock jumps on positive vitiligo trial data

Forte Biosciences (NASDAQ:FBRX) shares surged 12% after announcing positive results from its phase 1b study of FB102 for vitiligo. The treatment showed statistically significant improvement in FVASI from baseline, with 29.6% for FB102 compared to 7.9% for placebo, and even greate

Tone
Positive 94/100
Event
Earnings
Published
09 Jul 2026 12:09
Source
Investing.com
Investing.com Direct company coverage

Forte Biosciences reports positive phase 1b vitiligo trial results

Forte Biosciences announced positive results from its phase 1b double-blind placebo-controlled study of FB102 for vitiligo, showing a significant improvement in FVASI scores compared to placebo. The stock has seen substantial returns over the past year but is considered overvalue

Tone
Positive 74/100
Event
Earnings
Published
09 Jul 2026 12:09
Source
Investing.com
Stock Titan Direct company coverage

[8-K] Forte Biosciences, Inc. Reports Material Event

Forte Biosciences, Inc. (NASDAQ: FBRX) reported positive Phase 1b results for its drug candidate FB102 in treating vitiligo, demonstrating a statistically significant improvement in facial vitiligo area severity index (FVASI) compared to placebo. The study, involving 43 subjects,

Tone
Positive 72/100
Event
Earnings
Published
09 Jul 2026 12:09
Source
Stock Titan
Stock Titan Direct company coverage

Forte’s skin-disease drug showed measured gains through week 24

Forte Biosciences announced positive results from its FB102 double-blind placebo-controlled phase 1b study for vitiligo, showing statistically significant improvements in FVASI scores at week 24. The FB102-treated subjects continued to improve after the 12-week treatment period,

Tone
Positive 70/100
Event
Earnings
Published
09 Jul 2026 12:09
Source
Stock Titan
Stock Titan Direct company coverage

Federated Hermes (FBRX) shows 2.11M-share, 10.31% Schedule 13G/A stake

Federated Hermes, Inc. has filed an amended Schedule 13G/A, reporting a 2.11 million-share stake, representing 10.31% of Forte Biosciences (FBRX) common stock, as of June 30, 2026. The filing explicitly states disclaimers under Rule 13d-4, indicating that beneficial ownership of

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 11:40
Source
Stock Titan
www.marketscreener.com Direct company coverage

Certain Options of Forte Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026.

Certain stock options of Forte Biosciences, Inc. (FBRX) are under a lock-up agreement that will expire on July 8, 2026. This lock-up period, which started on April 8, 2026, prevents company executive officers and directors from selling or transferring these securities without con

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 00:39
Source
www.marketscreener.com
AD HOC NEWS Direct company coverage

Forte Biosciences Inc focuses on dermatology pipeline as investors weigh long-term prospects

Forte Biosciences Inc (FBRX) is a clinical-stage biotechnology company developing therapies for inflammatory skin diseases, with its business model relying on advancing experimental treatments through clinical trials and regulatory approval. The company's value for investors is t

Tone
Positive 65/100
Event
Regulatory and legal
Published
07 Jul 2026 16:39
Source
AD HOC NEWS
Stock Titan Direct company coverage

RSU vesting boosts holdings at Forte Biosciences (NASDAQ: FBRX)

Forte Biosciences director Paul A. Wagner reported exercising 1,250 restricted stock units (RSUs) on July 1, 2026, acquiring common stock at a $0.00 conversion price. A tax-withholding transaction involved 98 shares at $21.32 each, not an open-market sale. Post-transaction, Wagne

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 02:09
Source
Stock Titan
Finviz Direct company coverage

FBRX - Forte Biosciences Inc Options

This article provides a detailed financial overview of Forte Biosciences Inc (FBRX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider ownership, institutional ownership, and short

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 01:09
Source
Finviz